Together with ONWARD Co-Founders, Bryan, Garnier & Co hosted an exclusive Brain-Computer Interface (BCI) event on Thursday, 24 April 2025, at our Paris headquarters.

The event brought together a select group of institutional investors for a roundtable discussion with ONWARD’s co-founders, Prof. Grégoire Courtine, Neuroscientist, Co-Founder and Scientific Advisor at ONWARD Medical and Dr. Jocelyne Bloch, Neurosurgeon, Co-Founder and Medical Advisor at ONWARD Medical, to explore the transition from neuroscience research to entrepreneurship, with a deep dive into the emerging frontier of neurotechnology: BCI.

The session opened with remarks from Bryan, Garnier & Co highlighting the fast-evolving BCI space, its nascent commercial landscape, and the transformative potential for healthcare. This was followed by a candid and forward-looking conversation with ONWARD’s founders, who shared their journey, their vision, and the groundbreaking developments behind their ARC-BCI platform — a therapeutic system designed to restore movement by bridging the brain directly to the spinal cord.

ARC-BCI is set to be a revolutionary therapeutic device, whose secret sauce — as commented by the speakers — lies in the development of a brainGPT, aimed at empowering ARC-IM’s therapeutic potential by bridging to human thoughts.

Watch the full recording above to learn more.


ONWARD Medical is a medical technology company creating therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and movement disabilities. Building on more than a decade of science and preclinical research conducted at leading neuroscience laboratories, the Company has received ten Breakthrough Device Designations from the US Food and Drug Administration for its ARC Therapy™ platform.